The results indicated that NSCLC patients with high expression of LAPTM4B and SLC7A11 (LAPTM4Bhigh/SLC7A11high) has poor survival compared to the patients with low expression of LAPTM4B and SLC7A11 (LAPTM4Blow/SLC7A11low) (Fig. 7D). Here, SLC7A11 is linked to non-small cell lung carcinoma.